Infliximab Reduces Cardiac Output In Rheumatoid Arthritis Patients Without Heart Failure [infliximabe Reduz Débito Cardíaco Em Pacientes Com Artrite Reumatoide Sem Insuficiência Cardíaca]

dc.creatorSantos R.C.
dc.creatorFigueiredo V.N.
dc.creatorMartins L.C.
dc.creatorMoraes C.H.
dc.creatorQuinaglia T.
dc.creatorBoer-Martins L.
dc.creatorFerreira-Melo S.E.
dc.creatorYazbek M.A.
dc.creatorBertolo M.
dc.creatorMoreno Jr. H.
dc.date2012
dc.date2015-06-26T20:29:18Z
dc.date2015-11-26T14:25:49Z
dc.date2015-06-26T20:29:18Z
dc.date2015-11-26T14:25:49Z
dc.date.accessioned2018-03-28T21:28:32Z
dc.date.available2018-03-28T21:28:32Z
dc.identifier
dc.identifierRevista Da Associacao Medica Brasileira. , v. 58, n. 6, p. 698 - 702, 2012.
dc.identifier1044230
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84875496595&partnerID=40&md5=9bdceebab8805969b6e457a0bda3aeb9
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/96977
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/96977
dc.identifier2-s2.0-84875496595
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1245860
dc.descriptionObjective: Human anti-tumor necrosis factor (TNF-α) monoclonal antibody (infliximab) is used to treat autoimmune diseases such as rheumatoid arthritis (RA). Although the risk of worsening heart failure has been described in patients under chronic treatment, the acute cardiovascular effects of this drug are unknown in RA patients without heart failure. Methods: 14 RA patients with normal echocardiography and no history of heart failure were evaluated during the 2-hour infliximab (3-5 mg/kg) infusion period, using a noninvasive hemodynamic beat-to-beat system (Portapres). Stroke volume (SV); systolic, diastolic and mean blood pressures (SBP, DBP and MBP, respectively); cardiac output (CO); heart rate (HR); and total peripheral vascular resistance (PVR) were recorded. All patients also received saline infusion instead of infliximab as a control. Significant differences in hemodynamic parameters were determined using Tuckey's test. All values were expressed as mean ± standard deviation (SD). Results: Fourteen RA patients (6M/8F) with mean age of 47.2 ± 8.8 years were evaluated. A significant decrease was found in cardiac output and stroke volume (7.04 ± 2.3 to 6.12 ± 2.1 l/min and 91 ± 29.0 to 83 ± 28.8 mL/beat, respectively) after infliximab infusion. Although not statistically significant, a progressive increase was detected in SBP, DBP and total PVR during infusion. Saline infusion did not cause significant hemodynamic changes in the same group of RA patients. No adverse effects were observed during the infusion period. Conclusion: Acute infliximab administration decreased cardiac output due to low stroke volume in RA patients without heart disease. The results also demonstrated that, in spite of its negative inotropic effect, infliximab enhanced BP, probably by increasing PVR. © 2012 Elsevier Editora Ltda. All rights reserved.
dc.description58
dc.description6
dc.description698
dc.description702
dc.descriptionSmolen, J.S., Aletaha, D., Koeller, M., Weisman, M.H., Emery, P., New therapies for treatment of rheumatoid arthritis (2007) Lancet., 370, pp. 1861-1874
dc.descriptionDoan, T., Massarotti, E., Rheumatoid arthritis: An overview of new and emerging therapies (2005) J Clin Pharmacol., 45, pp. 751-762
dc.descriptionMann, D.L., Inflammatory mediators and the failing heart: Past, present, and the foreseeable future (2002) Circ Res., 91, pp. 988-998
dc.descriptionLysander, W.J., van Lieshout, J.J., Non-invasive pulsatile arterial pressure and stroke volume changes from the human finger (2005) Exp Physiol., 90, pp. 437-446
dc.descriptionWallberg-Jonsson, S., Johansson, H., Ohman, M.L., Rantapaa-Dahlqvist, S., Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset (1999) J Rheumatol., 26, pp. 2562-2571
dc.descriptionWolfe, F., Flowers, N., Burke, T.A., Arguelles, L.M., Pettitt, D., Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: Quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis (2002) J Rheumatol., 29, pp. 1015-1022
dc.descriptionBértolo, M.B., Brenol, C.V., Schainberg, C.G., Neubarth, F., Lima, F.A.C., Laurindo, I.M., Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide (2007) Rev Bras Reumatol., 47, pp. 151-159
dc.descriptionAletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham III, C.O., 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative (2010) Arthritis Rheum., 62, pp. 2569-2581
dc.descriptionLang, E.A., Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group (2005) J Am Soc Echocardiogr., 18, pp. 1440-1463
dc.descriptionEl Assaad, M.A., Topouchian, J.A., Darne, B.M., Asmar, R.G., Validation of the Omron HEM-907 device for blood pressure measurement (2002) Blood Press Monit., 7, pp. 237-241
dc.descriptionChobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr., J.L., The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA., 289, pp. 2560-2572
dc.descriptionLangewouters, G.J., Settels, J.J., Roelandt, R., Wesseling, K.H., Why use Finapres or Portapres rather than intra-arterial or intermittent non-invasive techniques of blood pressure measuremant? (1998) J Med Eng Technol., 22, pp. 37-43
dc.descriptionJansen, J.R.C., Schreuder, J.J., Mulier, J.P., Smith, N.T., Settels, J.J., Wesseling, K.H., A comparison of cardiac output derived from the arterial pressure wave against thermodilution in cardiac surgery patients (2001) Br J Anaesth., 87, pp. 212-222
dc.descriptionLeonetti, P., Audat, F., Girard, A., Laude, D., Lefrère, F., Elghozi, J., Stroke volume monitored by modeling flow from finger arterial pressure waves mirrors blood volume withdrawn by phlebotomy (2004) Clin Auton Res., 14, pp. 176-181
dc.descriptionRamey, D.R., Raynauld, J.P., Fries, J.F., The health assessment questionnaire 1992: Status and review (1992) Arthritis Care Res., 5, pp. 119-129
dc.descriptionWolfe, F., A reappraisal of HAQ disability in rheumatoid arthritis (2000) Arthritis Rheum., 43, pp. 2751-2761
dc.descriptionKumar, A., Anel, R., Bunnell, E., Habet, K., Neumann, A., Wolff, D., Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers (2004) Intensive Care Med., 30, pp. 1361-1369
dc.descriptionKu, I.A., Imboden, J.B., Hsue, P.Y., Ganz, P., Rheumatoid arthritis: Model of systemic inflammation driving atherosclerosis (2009) Circ J., 73, pp. 977-985
dc.descriptionvan de Putte, L.B., Atkins, C., Malaise, M., Sany, J., Russell, A.S., van Riel, P.L., Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed (2004) Ann Rheum Dis., 63, pp. 508-516
dc.descriptionWeinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial (2003) Arthritis Rheum., 48, pp. 35-45
dc.descriptionMann, D.L., McMurray, J.J., Packer, M., Swedberg, K., Borer, J.S., Colucci, W.S., Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) (2004) Circulation., 109, pp. 1594-1602
dc.descriptionChung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A., Willerson, J.T., Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial (2003) Circulation., 107, pp. 3133-3140
dc.descriptionKubota, T., Bounoutas, G.S., Miyagishima, M., Kadokami, T., Sanders, V.J., Bruton, C., Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy (2000) Circulation., 101, pp. 2518-2525
dc.descriptionKadokami, T., Frye, C., Lemster, B., Wagner, C.L., Feldman, A.M., McTiernan, C.F., Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model (2001) Circulation., 104, pp. 1094-1097
dc.descriptionZink, A., Strangfeld, A., Schneider, M., Herzer, P., Hierse, F., Stoyanova-Scholz, M., Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials (2006) Arthritis Rheum., 54, pp. 3399-3407
dc.descriptionKhaper, N., Bryan, S., Dhingra, S., Singal, R., Bajaj, A., Pathak, C.M., Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure (2010) Antioxid Redox Signal., 13, pp. 1033-1049
dc.descriptionGiordano, F.J., Oxygen, oxidative stress, hypoxia, and heart failure (2005) J Clin Invest., 115, pp. 500-508
dc.descriptionMatsuzawa, A., Ichijo, H., Redox control of cell fate by MAP kinase: Physiological roles of ASK1-MAP kinase pathway in stress signaling (2008) Biochim Biophys Acta., 1780, pp. 1325-1336
dc.descriptionScallon, B.J., Moore, M.A., Trinh, H., Knight, D.M., Ghrayeb, J., Chimeric anti-TNFalpha monoclonal antibody cA2 binds recombinant transmembrane TNFalpha and activates immune effector functions (1995) Cytokine., 7, pp. 251-259
dc.languageen
dc.languagept
dc.publisher
dc.relationRevista da Associacao Medica Brasileira
dc.rightsfechado
dc.sourceScopus
dc.titleInfliximab Reduces Cardiac Output In Rheumatoid Arthritis Patients Without Heart Failure [infliximabe Reduz Débito Cardíaco Em Pacientes Com Artrite Reumatoide Sem Insuficiência Cardíaca]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución